|
[1]
|
Kang, Y., Cai, Y. and Zhang, H. (2017) Gut Microbiota and Allergy/Asthma: From Pathogenesis to New Therapeutic Strategies. Allergologia et Immunopathologia, 45, 305-309. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Samuelson, D.R., Welsh, D.A. and Shellito, J.E. (2015) Regulation of Lung Immunity and Host Defense by the Intestinal Microbiota. Frontiers in Microbiology, 6, Article No. 1085. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Budden, K.F., Gellatly, S.L., Wood, D.L., et al. (2017) Emerging Pathogenic Links between Microbiota and the Gut-Lung Axis. Nature Reviews Microbiology, 15, 55-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Jia, W., Xie, G. and Jia, W. (2018) Bile Acid-Microbiota Crosstalk in Gastrointestinal Inflammation and Carcinogenesis. Nature Reviews Gastroenterology & Hepatology, 15, 111-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Dai, Z., Zhang, J., Wu, Q., et al. (2019) The Role of Microbiota in the Development of Colorectal Cancer. International Journal of Cancer, 145, 2032-2041. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Peterson, L.W. and Artis, D. (2014) Intestinal Epithelial Cells: Regulators of Barrier Function and Immune Homeostasis. Nature Reviews Immunology, 14, 141-153. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kho, Z.Y. and Lal, S.K. (2018) The Human Gut Microbiome—A Potential Controller of Wellness and Disease. Frontiers in Microbiology, 9, Article No. 1835. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Mithieux, G. (2018) Gut Nutrient Sensing and Microbiota Function in the Control of Energy Homeostasis. Current Opinion in Clinical Nutrition & Metabolic Care, 21, 273-276. [Google Scholar] [CrossRef]
|
|
[9]
|
Chow, J., Tang, H. and Mazmanian, S.K. (2011) Pathobi-onts of the Gastrointestinal Microbiota and Inflammatory Disease. Current Opinion in Immunology, 23, 473-480. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Zechner, E.L. (2017) Inflammatory Disease Caused by Intestinal Pathobionts. Current Opinion in Microbiology, 35, 64-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Garrett, W.S. (2015) Cancer and the Microbiota. Science (New York, NY), 348, 80-86. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Khan, A.A., Shrivastava, A. and Khurshid, M. (2012) Normal to Cancer Microbiome Transformation and Its Implication in Cancer Diagnosis. Biochimica et Biophysica Acta, 1826, 331-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Mao, Q., Jiang, F., Yin, R., et al. (2018) Interplay be-tween the Lung Microbiome and Lung Cancer. Cancer Letters, 415, 40-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Amieva, M. and Peek, R.M. (2016) Pathobiology of Helicobacter pylori-Induced Gastric Cancer. Gastroenterology, 150, 64-78. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Moss, S.F. (2017) The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cellular Molecular Gastroenterology Hepatology, 3, 183-191. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Schwabe, R.F. and Jobin, C. (2013) The Microbiome and Cancer. Nature Reviews Cancer, 13, 800-812. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Kroemer, G. and Zitvogel, L. (2018) Cancer Immunotherapy in 2017: The Breakthrough of the Microbiota. Nature Reviews Immunology, 18, 87-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Mur, L.A., Huws, S.A., Cameron, S.J., et al. (2018) Lung Cancer: A New Frontier for Microbiome Research and Clinical Translation. Ecancermedicalscience, 12, Article No. 866. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Zhang, W.Q., Zhao, S.K., Luo, J.W., et al. (2018) Alterations of Fe-cal Bacterial Communities in Patients with Lung Cancer. American Journal of Translational Research, 10, 3171-3185.
|
|
[20]
|
Bingula, R., Filaire, M., Radosevic-Robin, N., et al. (2017) Desired Turbulence? Gut-Lung Axis, Im-munity, and Lung Cancer. Journal of Oncology, 2017, Article ID: 5035371. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Sivaprakasam, S., Gurav, A., Paschall, A.V., et al. (2016) An Essential Role of Ffar2 (Gpr43) in Dietary Fibre-Mediated Promotion of Healthy Composition of Gut Microbiota and Suppression of Intestinal Carcinogenesis. Oncogenesis, 5, e238. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Liu, H., Wang, J., He, T., et al. (2018) Butyrate: A Double-Edged Sword for Health? Advances in Nutrition, 9, 21-29. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Conte, M., De Palma, R. and Altucci, L. (2018) HDAC Inhibitors as Epigenetic Regulators for Cancer Immunotherapy. The International Journal of Biochemistry & Cell Biology, 98, 65-74. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Gui, Q., Li, H., Wang, A., et al. (2020) The Association between Gut Butyrate-Producing Bacteria and Non-Small-Cell Lung Cancer. Journal of Clinical Laboratory Analysis, 34, e23318. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Biragyn, A. and Ferrucci, L. (2018) Gut Dysbiosis: A Potential Link be-tween Increased Cancer Risk in Ageing and Inflammaging. The Lancet Oncology, 19, e295-e304. [Google Scholar] [CrossRef]
|
|
[26]
|
Zitvogel, L., Daillère, R., Roberti, M.P., et al. (2017) Anti-cancer Effects of the Microbiome and Its Products. Nature Reviews Microbiology, 15, 465-478.
|
|
[27]
|
Zhuang, H., Cheng, L., Wang, Y., et al. (2019) Dysbiosis of the Gut Microbiome in Lung Cancer. Frontiers in Cellular and Infection Micro-biology, 9, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Bingula, R., et al. (2018) Characterisa-tion of Gut, Lung, and Upper Airways Microbiota in Patients with Non-Small Cell Lung Carcinoma: Study Protocol for Case-Control Observational Trial. Medicine (Baltimore), 97, e13676.
|
|
[29]
|
Carbone, C., Piro, G., Noia, V.D., et al. (2019) Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation, 2019, Article ID: 7652014. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Zheng, Y., Fang, Z., Xue, Y., et al. (2020) Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer. Gut Microbes, 11, 1030-1042. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Fu, A., Yao, B., Dong, T., et al. (2022) Tumor-Resident In-tracellular Microbiota Promotes Metastatic Colonization in Breast Cancer. Cell, 185, 1356-72.e26. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Wisinski, K. and Benson, A. (2007) Chemotherapy-Induced Mu-cositis: Focusing on Diarrhea. The Journal of Supportive Oncology, 5, 270-271.
|
|
[33]
|
Stringer, A.M., Gibson, R.J., Bowen, J.M., et al. (2007) Chemotherapy-Induced Mucositis: The Role of Gastrointestinal Microflora and Mucins in the Luminal Environment. The Journal of Supportive Oncology, 5, 259-267.
|
|
[34]
|
Zitvogel, L., Galluzzi, L., Viaud, S., et al. (2015) Cancer and the Gut Microbiota: An Unexpected Link. Science Translational Medicine, 7, 271ps1. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Bingula, R. and Filaire, M. (2017) Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Journal of Oncology, 2017, Article ID: 5035371. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Daillère, R., Vétizou, M., Waldschmitt, N., et al. (2016) Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 45, 931-943. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Bingula, R., Filaire, M., Radosevic-Robin, N., et al. (2018) Characterisation of Gut, Lung, and Upper Airways Microbiota in Patients with Non-Small Cell Lung Carcinoma: Study Protocol for Case-Control Observational Trial. Medicine (Baltimore), 97, e13676. [Google Scholar] [CrossRef]
|
|
[38]
|
Gui, Q.F., Lu, H.F., Zhang, C.X., et al. (2015) Well-Balanced Commensal Microbiota Contributes to Anti-Cancer Response in a Lung Cancer Mouse Model. Genetics and Molecular Research, 14, 5642-5651. [Google Scholar] [CrossRef]
|
|
[39]
|
Zhao, Y., Liu, Y., Li, S., et al. (2021) Role of Lung and Gut Micro-biota on Lung Cancer Pathogenesis. Journal of Cancer Research and Clinical Oncology, 147, 2177-2186. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Crawford, P.A. and Gordon, J.I. (2005) Microbial Regulation of Intestinal Radiosensitivity. Proceedings of the National Academy of Sciences of the United States of America, 102, 13254-13259. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Borghaei, H., Paz-Ares, L., Horn, L., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639. [Google Scholar] [CrossRef]
|
|
[42]
|
Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. [Google Scholar] [CrossRef]
|
|
[43]
|
Herbst, R.S., Baas, P., Kim, D.W., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet (London, England), 387, 1540-1550. [Google Scholar] [CrossRef]
|
|
[44]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef]
|
|
[45]
|
Guo, R., Chen, X., Wang, T., et al. (2011) Subsequent Chemother-apy Reverses Acquired Tyrosine Kinase Inhibitor Resistance and Restores Response to Tyrosine Kinase Inhibitor in Ad-vanced Non-Small-Cell Lung Cancer. BMC Cancer, 11, Article No. 90. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Rudin, C.M., Brambilla, E., Faivre-Finn, C., et al. (2021) Small-Cell Lung Cancer. Nature Reviews Disease Primers, 7, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Reck, M., Luft, A., Szczesna, A., et al. (2016) Phase III Ran-domized Trial of Ipilimumab plus Etoposide and Platinum versus Placebo plus Etoposide and Platinum in Exten-sive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 3740-3748. [Google Scholar] [CrossRef]
|
|
[48]
|
Routy, B., Le Chatelier, E., Derosa, L., et al. (2018) Gut Microbi-ome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science (New York, NY), 359, 91-97. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Sistigu, A., Viaud, S., Chaput, N., et al. (2011) Immunomodulatory Effects of Cyclophosphamide and Implementations for Vaccine Design. Seminars in Immunopathology, 33, 369-383. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Sivan, A., Corrales, L., Hubert, N., et al. (2015) Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science (New York, NY), 350, 1084-1089. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Belcheva, A., Irrazabal, T. and Martin, A. (2015) Gut Microbial Metabolism and Colon Cancer: Can Manipulations of the Microbiota Be Useful in the Management of Gastro-intestinal Health? Bioessays, 37, 403-412. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Katayama, Y., et al. (2019) The Role of the Gut Microbiome on the Efficacy of Immune Checkpoint Inhibitors in Japanese Responder Patients with Advanced Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 8, 847-853. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Jin, A.Y., Hui, D.B., et al. (2019) The Diversity of Gut Microbiome Is Associated with Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients with NSCLC. Journal of Thoracic Oncology, 14, 1378-1389. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Liu, F., Li, J., Guan, Y., et al. (2019) Dysbiosis of the Gut Micro-biome Is Associated with Tumor Biomarkers in Lung Cancer. International Journal of Biological Sciences, 15, 2381-2392. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
袁文杰. 非小细胞肺癌患者菌群结构特征初步探索[D]: [硕士学位论文]. 北京: 北京市结核病胸部肿瘤研究所, 2021.
|
|
[56]
|
Dubin, K., Callahan, M.K., Ren, B., et al. (2016) Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nature Communications, 7, Article No. 10391. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Chaput, N., Lepage, P., Coutzac, C., et al. (2017) Baseline Gut Micro-biota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated with Ipilimumab. Annals of Oncol-ogy: Official Journal of the European Society for Medical Oncology, 28, 1368-1379. [Google Scholar] [CrossRef] [PubMed]
|